U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. About FDA
  3. FDA Organization
  4. Center for Drug Evaluation and Research (CDER)
  5. CDER Offices and Divisions
  6. Office of Communications
  1. CDER Offices and Divisions

Office of Communications

Center for Drug and Evaluation Research (CDER)

Who We Are

2023 CDER Office of Communications Annual Report

2023 Annual Report Office of Communications
(PDF - 6 MB)

CDER’s Office of Communications (OCOMM) supports FDA’s mission to protect and promote public health. OCOMM is the primary resource for communicating human drug information with staff that includes health professionals, communications specialists, and web and graphic designers.

What We Do

  • Provide strategic communication advice to center and agency leadership.
  • Develop and coordinate overarching public communication initiatives and educational activities.
  • Employ comprehensive communication approaches to ensure consistent branding, messaging, and strategic direction of CDER’s communication products.
  • Collaborate with internal and external partners and stakeholders.
  • Provide expertise on multimedia communication products that inform and educate.
  • Manage CDER’s risk communication, social marketing and health literacy research activities.
  • Develop Drug Safety Communications to update patients, caregivers, health care professionals and the public with new information about potential risks of FDA-approved drugs.
  • Provide leadership and direction for developing, assessing, communicating, and implementing an advocacy and stakeholder relations strategy for CDER.
  • Conduct research to ensure that CDER has a thorough understanding of partner, stakeholder, and public opinion about issues of interest to CDER.

Office Organization

Contact Us

Email: druginfo@fda.hhs.gov

Hillandale Building, 10001 New Hampshire Avenue, Silver Spring, MD 20993



Back to Top